AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
27 avr. 2023 14h41 HE
|
AB Science
PRESS RELEASE AB SCIENCE SUMMARIZES THE PRESENTATION ON MASITTINIB IN AMYOTROPHIC LATERAL SCLEROSIS MADE AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING, INCLUDING LONG-TERM SURVIVAL...
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
25 avr. 2023 16h01 HE
|
Athira Pharma, Inc.
Fosgonimeton improves MMSE (mini-mental state evaluation) after six months in a post hoc analysis from the Phase 2 ACT-AD trial in mild-to-moderate Alzheimer’s disease Preclinical findings with...
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
25 avr. 2023 15h52 HE
|
Muscular Dystrophy Association
New York, April 25, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of Qalsody (tofersen), for the...
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
25 avr. 2023 15h04 HE
|
Biogen Inc.
FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration1Superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) is a devastating,...
Muscular Dystrophy Association Announces Programming for ALS Awareness Month
24 avr. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, April 24, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced programming and fundraising events in support of people living with Amyotrophic Lateral...
AB Science annonce l’obtention d’un brevet sur le masitinib au Japon pour le traitement de la sclérose latérale amyotrophique, renforçant ainsi la position de la société en matière de propriété intellectuelle jusqu’en 2037
18 avr. 2023 12h55 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE L'OBTENTION D'UN BREVET SUR LE MASITINIB AU JAPON POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE, RENFORÇANT AINSI LA POSITION DE LA SOCIÉTÉ EN...
AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037
18 avr. 2023 12h55 HE
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES MASITINIB PATENT GRANTED IN JAPAN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, STRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION UNTIL 2037 TO...
AB Science : Les résultats du masitinib dans la SLA seront présentés à l’AAN 2023, et incluent l’analyse de la survie à long terme et une nouvelle analyse concernant la population de patients sans perte fonctionnelle à l'inclusion
12 avr. 2023 12h23 HE
|
AB Science
COMMUNIQUE DE PRESSE LES RÉSULTATS DU MASITINIB DANS LA SLA ONT ÉTÉ SÉLECTIONNÉS POUR UNE PRÉSENTATION SCIENTIFIQUE À LA RÉUNION ANNUELLE 2023 DE L'AMERICAN ACADEMY OF NEUROLOGY, ET INCLUENT...
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
12 avr. 2023 12h23 HE
|
AB Science
PRESS RELEASE RESULTS OF MASITINIB IN ALS SELECTED FOR A SCIENTIFIC PLATFORM PRESENTATION AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING, INCLUDING LONG-TERM SURVIVAL...
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
11 avr. 2023 07h00 HE
|
Athira Pharma, Inc.
Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer’s disease patients including improvements in measures of cognition and...